In a report released on January 21, Brian Abrahams from RBC Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...

Investment analysts at Leerink Partnrs upped their FY2024 earnings per share (EPS) estimates for Sarepta Therapeutics in a report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by gene therapy. Despite past valuation ...

Analysts at HC Wainwright raised their FY2024 earnings estimates for Sarepta Therapeutics in a note issued to investors on ...

We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Disruptive analytics’ Substack by Magnus Ofstad. In ...

SRPT insiders have traded $SRPT stock on the open market 6 times in the past 6 months. Of those trades, 3 have been purchases and 3 have been sales. Here’s a ...

The Speak Foundation will host the fourth International Limb Girdle Muscular Dystrophy (LGMD) Conference at the J.W. Marriott ...

The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

View Sarepta Therapeutics, Inc. (SRPT) current and estimated P/E ratio data provided by Seeking Alpha.